...
cybn-img

Cybin Inc, Common Stock

CYBN

ASQ

$10.43

-$0.14

(-1.32%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$211.31M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
230.95K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.89
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.5 L
$19.84 H
$10.43

About Cybin Inc, Common Stock

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCYBNSectorS&P500
1-Week Return1.76%-0.09%0.83%
1-Month Return3.06%0.03%5.98%
3-Month Return17.3%-6.26%9.65%
6-Month Return-17.33%1.16%14.29%
1-Year Return-38.6%11.16%32.26%
3-Year Return-78.22%11.98%31.61%
5-Year Return-79.26%47.19%94.03%
10-Year Return-79.26%109.06%191.47%

Financials

Mar '20Mar '21Mar '22Mar '23Mar '245YR TREND
Total Revenue-864.00K---[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Cost of Revenue-664.00K168.00K251.00K424.00K[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":25.3,"profit":true},{"date":"2023-03-31","value":37.8,"profit":true},{"date":"2024-03-31","value":63.86,"profit":true}]
Gross Profit-200.00K(168.00K)(251.00K)(424.00K)[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":-84,"profit":false},{"date":"2023-03-31","value":-125.5,"profit":false},{"date":"2024-03-31","value":-212,"profit":false}]
Gross Margin-23.15%(Infinity%)(Infinity%)(Infinity%)[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":null,"profit":false},{"date":"2023-03-31","value":null,"profit":false},{"date":"2024-03-31","value":null,"profit":false}]
Operating Expenses1.94M30.72M63.84M51.52M78.84M[{"date":"2020-03-31","value":2.47,"profit":true},{"date":"2021-03-31","value":38.97,"profit":true},{"date":"2022-03-31","value":80.98,"profit":true},{"date":"2023-03-31","value":65.35,"profit":true},{"date":"2024-03-31","value":100,"profit":true}]
Operating Income(1.95M)(30.46M)(63.60M)(54.94M)(78.84M)[{"date":"2020-03-31","value":-195360000,"profit":false},{"date":"2021-03-31","value":-3046400000,"profit":false},{"date":"2022-03-31","value":-6359700000,"profit":false},{"date":"2023-03-31","value":-5494300000,"profit":false},{"date":"2024-03-31","value":-7883600000,"profit":false}]
Total Non-Operating Income/Expense-(1.14M)(3.55M)4.63M1.38M[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":-24.51,"profit":false},{"date":"2022-03-31","value":-76.7,"profit":false},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":29.69,"profit":true}]
Pre-Tax Income(1.94M)(32.22M)(67.63M)(47.49M)(78.08M)[{"date":"2020-03-31","value":-194400000,"profit":false},{"date":"2021-03-31","value":-3222000000,"profit":false},{"date":"2022-03-31","value":-6763100000,"profit":false},{"date":"2023-03-31","value":-4749000000,"profit":false},{"date":"2024-03-31","value":-7808000000,"profit":false}]
Income Taxes9.6010.00K3.79M(7.45M)-[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":0.26,"profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":-196.49,"profit":false},{"date":"2024-03-31","value":"-","profit":true}]
Income After Taxes-(32.23M)(71.42M)(40.04M)-[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":-3223000000,"profit":false},{"date":"2022-03-31","value":-7142400000,"profit":false},{"date":"2023-03-31","value":-4003700000,"profit":false},{"date":"2024-03-31","value":"-","profit":true}]
Income From Continuous Operations-(32.22M)(67.63M)(47.49M)(78.08M)[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":-3222000000,"profit":false},{"date":"2022-03-31","value":-6763100000,"profit":false},{"date":"2023-03-31","value":-4749000000,"profit":false},{"date":"2024-03-31","value":-7808000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Net Income(1.94M)(32.22M)(71.42M)(40.04M)(78.08M)[{"date":"2020-03-31","value":-194400000,"profit":false},{"date":"2021-03-31","value":-3222000000,"profit":false},{"date":"2022-03-31","value":-7142400000,"profit":false},{"date":"2023-03-31","value":-4003700000,"profit":false},{"date":"2024-03-31","value":-7808000000,"profit":false}]
EPS (Diluted)-(0.18)(0.40)(0.26)(0.23)[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":-18,"profit":false},{"date":"2022-03-31","value":-40,"profit":false},{"date":"2023-03-31","value":-26,"profit":false},{"date":"2024-03-31","value":-23,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CYBN
Cash Ratio 20.93
Current Ratio 24.24

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CYBN
ROA (LTM) -32.71%
ROE (LTM) -49.07%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CYBN
Debt Ratio Lower is generally better. Negative is bad. 0.03
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.97

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CYBN
Trailing PE NM
Forward PE NM
P/S (TTM) 278.25
P/B 1.16
Price/FCF NM
EV/R 313.59
EV/Ebitda NM

FAQs

What is Cybin Inc share price today?

Cybin Inc (CYBN) share price today is $10.43

Can Indians buy Cybin Inc shares?

Yes, Indians can buy shares of Cybin Inc (CYBN) on Vested. To buy Cybin Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CYBN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Cybin Inc be purchased?

Yes, you can purchase fractional shares of Cybin Inc (CYBN) via the Vested app. You can start investing in Cybin Inc (CYBN) with a minimum investment of $1.

How to invest in Cybin Inc shares from India?

You can invest in shares of Cybin Inc (CYBN) via Vested in three simple steps:

  • Click on Sign Up or Invest in CYBN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Cybin Inc shares
What is Cybin Inc 52-week high and low stock price?

The 52-week high price of Cybin Inc (CYBN) is $19.84. The 52-week low price of Cybin Inc (CYBN) is $6.5.

What is Cybin Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Cybin Inc (CYBN) is

What is Cybin Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Cybin Inc (CYBN) is 1.16

What is Cybin Inc dividend yield?

The dividend yield of Cybin Inc (CYBN) is 0.00%

What is the Market Cap of Cybin Inc?

The market capitalization of Cybin Inc (CYBN) is $211.31M

What is Cybin Inc’s stock symbol?

The stock symbol (or ticker) of Cybin Inc is CYBN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top